OPEN END-TURBO-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 11:05:25 02/07/2024 pm IST | ||
| 6.6 EUR | -1.35% |
|
| Current month | -1.76% | ||
| 1 month | +8.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 6.6 | -1.35% |
| 01/24/01 | 6.69 | -1.76% |
| 28/24/28 | 6.81 | -1.02% |
| 27/24/27 | 6.88 | -1.43% |
| 26/24/26 | 6.98 | -7.43% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 11:05 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | HSBC |
| WKN | HS0WMQ |
| ISIN | DE000HS0WMQ5 |
| Date issued | 21/07/2023 |
| Strike | 239.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.82 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.62 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.02 € |
| Spread % | 0.30% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311
USD
Average target price
316.4
USD
Spread / Average Target
+1.75%
- Stock Market
- Certificates
- Certificat
